

**WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016**

Drug classes not included on this list are not managed through a Preferred Drug List (PDL).
HOWEVER, THIS EXCLUSION IS NOT A GUARANTEE OF PAYMENT OR COVERAGE. Dosage limits and other requirements may apply.
Drugs new to market are non-preferred until a clinical review has been completed. PA criteria will apply to both the pediatric population,
as well as the adult population for those plans where PA/PDL limits are allowed.
Unless otherwise noted on the PDL, generic substitution is mandatory.

Yellow highlighted items below indicate new changes to the PDL. Red font indicates quantity/dosage limits apply. *Indicates BRAND is Preferred. May Use DAW 5.
Contact the Change Healthcare PA Helpdesk @ 877-207-1126 for prior authorization if client has primary insurance that will not cover the brand name medication.

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.**

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>PLEASE CONTACT CHANGE HEALTHCARE FOR QUESTIONS</small>
ADDICTION AGENTS	BUPRENORPHINE COMBINATIONS SUBOXONE FILM		Client must have a diagnosis of opioid dependence or abuse. This is not to be used for the treatment of chronic pain. Prescriber must have a XDEA number. Prior authorization will be required before any narcotic or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any benzodiazepine or short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills. Oral buprenorphine will be approved for clients that are pregnant or nursing or with a documented allergy to naloxone. Please submit PA requests on the "Oral Buprenorphine/Naloxone or Oral Buprenorphine" PA form available at www.wymedicaid.org . Dosage limits apply During first two years of treatment: 16mg After two years of treatment: 8mg	BUNAVAIL buprenorphine (oral) buprenorphine/naloxone tablets (use preferred) ZUBSOLV
	NALTREXONE naltrexone VIVITROL		Client must have a diagnosis of alcohol or opioid dependence. Prior authorization will be required before any narcotic or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any benzodiazepine or short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills.	
ALLERGY / ASTHMA	ANTIHISTAMINES, MINIMALLY SEDATING cetirizine fexofenadine loratadine		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	desloratadine CLARINEX RDT/SYRUP levocetirizine
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	CLARINEX-D
	ANTICHOLINERGIC BRONCHODILATORS ipratropium SPIRIVA HANDHALER		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Spiriva 5 day STARTER package will be allowed one (1) time per recipient.	ATROVENT HFA INCRUSE ELLIPTA SPIRIVA RESPIMAT (use preferred agent) TUDORZA
	INHALED COMBINATION AGENTS ADVAIR DISK/HFA COMBIVENT DULERA SYMBICORT		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. ***Will also require the diagnosis of COPD. Advair 7 and 14-day STARTER package will be allowed one (1) time per recipient.	ANORO ELLIPTA*** BREQ ELLIPTA*** STIOLTO
	LEUKOTRIENE MODIFIERS montelukast		Trial and failure of preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	zafirlukast ZYFLO
	LONG ACTING BRONCHODILATORS BROVANA SEREVENT		Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	PERFOROMIST STRIVERDI
	NASAL ANTIHISTAMINES ASTELIN azelastine 0.1%		Trial and failure of preferred agent greater than or equal to 90 days in the last 12 months will be required before approval can be given for a non-preferred agent.	azelastine 0.15% AZENASE (use separate agents) DYMISTA (use separate agents) olopatadine 0.6%
	NASAL STEROIDS BECONASE AQ flunisolide fluticasone NASONEX*		Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Budesonide will be approved for pregnancy.	AZENASE (use separate agents) budesonide DYMISTA (use separate agents) OMNARIS QNASL TICANASE (use separate agents) triamcinolone VERAMYST ZETONNA
	SHORT ACTING BRONCHODILATORS - INHALERS PROAIR HFA PROVENTIL HFA VENTOLIN HFA		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Minimum day supply of at 16 days is required	PROAIR RESPICLIK XOPENEX HFA
	SHORT ACTING BRONCHODILATORS - NEBULIZERS albuterol neb levalbuterol neb		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR HEALTH CARE PROVIDER</small>
ALLERGY / ASTHMA continued	STEROID INHALANTS		Trial and failure of three (3) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Alvesco will be approved for a history of oral thrush with steroid inhalants.	AEROBID/AEROBID-M ALVESCO ARNUITY ASMANEX budesonide susp 0.25mg/2ml AND 0.5mg/2ml (BRAND IS PREFERRED) budesonide susp 1mg/2ml QVAR
	AEROSPAN FLOVENT HFA/DISK PULMICORT SUSP 0.25mg/2ml AND 0.5mg/2ml* PULMICORT FLEXHALER			
	EPINEPHRINE			ADRENALINE (use preferred agent) ALVI-Q (use preferred agent) epinephrine (use preferred agent)
ALZHEIMERS	ALZHEIMER AGENTS		Client must have a diagnosis of dementia.	donepezil 23mg (use preferred agent) donepezil ODT (use preferred agent) rivastigmine patches (BRAND IS PREFERRED)
		donepezil EXELON PATCH* galantamine/ER memantine tablets/solution NAMENDA XR rivastigmine capsules		
ANALGESICS	LONG-ACTING C-Its		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. C-Its and C-IVs that are not included on the PDL and are available without prior authorization with the exception of Butrans (generic substitution is mandatory). Concurrent use of a narcotic and benzodiazepine will require prior authorization Fentanyl patches will require a prior authorization unless a client has a cancer diagnosis or previous treatment of at least a 10 day supply within the last 45 days **Butrans requires a trial of morphine sulfate ER or low dose trial of fentanyl patch. ***Nucynta ER will be allowed for diabetic peripheral neuropathy or clients with significant gastrointestinal concerns with other CII narcotics. ****In addition to above criteria, Embeda requires a diagnosis of drug/substance abuse. Fentanyl patches are limited to one patch every 72 hours. Belbuca: 1.8mg/day (1800mcg/day) Butrans: 20mcg, 1 strength at a time, 1 patch every 7 days Fentanyl: 75mcg, 1 strength at a time, 1 patch every 3 days Hysingla ER: 180mg/day Hydromorphone ER: 32mg/day Morphine ER: 180mg/day Methadone: Limited to 3 tablets per day Nucynta ER: 490.5mg/day Oxycontin: 120mg/day Oxymorphone ER: 60mg/day Xartemis XR: 120mg/day Xtampza ER: 120mg/day Zohydro ER: 180mg/day Clients will be limited to one long-acting narcotic at a time	AVINZA BELBUCA BUTRANS** EMBEDA**** fentanyl patch 37.5, 62.5, 87.5mg hydromorphone ER HYSINGLA ER (additional criteria applies) KADIAN 200mg (use preferred agent) METHADONE morphine sulfate ER capsules (use preferred) NUCYNTA ER*** oxymorphone ER OXYCONTIN* XARTEMIS XR (additional criteria applies) XTAMPZA ER (additional criteria applies) ZOHYDRO ER (additional criteria applies)
	morphine sulfate ER tablets	fentanyl patch 12.5, 25, 50, 75, and 100mg		
	SHORT-ACTING C-Its			
	codeine sulfate hydrocodone/APAP hydrocodone/IBU hydromorphone LORTAB ELIXIR 10-300MG meperidine morphine sulfate oxycodone oxycodone/APAP oxycodone/ASA			levorphanol NUCYNTA* oxymorphone oxycodone/IBU
	C-III/C-V AGENTS		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Quantity and dosage limits apply (max 8 tabs/day). **Butrans will require a 14 day trial and failure of tramadol IR and a 14 day trial and failure of tramadol ER prior to approval	BUTRANS** RYBIX ODT tramadol/apap tramadol ER capsules tramadol ER tablets
	tramadol			
ANDROGENS	TESTOSTERONE TOPICAL GELS		Testosterone agents are only allowed for diagnosis of hypogonadism or insufficient testosterone production. Other testosterone dosage form products will require a diagnosis of hypogonadism or insufficient testosterone production (not outlined on PDL).	NATESTO NASAL GEL (use preferred agent) TESTIM GEL (use preferred agent) testosterone gel 1% (BRAND IS PREFERRED) testosterone gel 2% (use preferred agent) VOGELXO GEL (use preferred agent)
		ANDROGEL*		

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR HEALTH CARE PROVIDER FOR QUESTIONS</small>
ANTIBIOTICS	QUINOLONES			FACTIVE moxifloxacin NOROXIN PROQUIN
	ciprofloxacin/ER levofloxacin ofloxacin			ADOXA (use preferred agent) DORYX (use preferred agent) ORACEA (use preferred agent)
	DOXYCYCLINE			SOLODYN (use preferred agent)
	doxycycline			
	MINOCYCLINE			
ANTICOAGULANTS	LOW MOLECULAR WEIGHT HEPARIN (LMWH)		Prior authorization will be required for the 300mg/3ml strength	FRAGMIN (use preferred agent) LOVENOX 300MG/3ML*
	enoxaparin			
	DIRECT THROMBIN INHIBITOR			
		PRADAXA	Client must have diagnosis of non-valvular atrial fibrillation and relative contraindication to warfarin for approval, treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE), or for the reduction in the risk of recurrence of DVT and PE after initial therapy.	
ANTICONSULSANTS	SELECTIVE FACTOR XA INHIBITOR		Client must have diagnosis of non-valvular atrial fibrillation, treatment for deep vein thrombosis (DVT) prophylaxis in knee or hip replacement, treatment of DVT and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE after initial therapy.	SAVAYSA (use preferred agent)
		ELIQUIS XARELTO		
	DIAZEPAM RECTAL GEL			diazepam gel (BRAND IS PREFERRED)
ANTIDEPRESSANTS	DIATAT*			
	ORAL ANTICONSULSANTS		Limited to FDA approved indications	
		FYCOMPA VIMPAT		
	ANTIDEPRESSANTS		Trial and failure of two (2) preferred agents greater than or equal to six (6) weeks WITHIN THE LAST 2 YEARS will be required before approval can be given for a non-preferred agent. One of the trials of preferred agents must be in the same class (NaSS, NDRI, SSRI, or SNRI) as the requested non-preferred agent.	NaSS NDRI SSRI SNRI
ANTIDEPRESSANTS	NORADRENERGIC/SPECIFIC SEROTONERICS (NaSS)			NaSS
	mirtazapine 15, 30, and 45mg			mirtazapine 7.5mg and rapid dissolve tablets (use preferred agent)
	NOREPINEPHRINE/DOPAMINE REUPTAKE INHIBITORS (NDRI)			NDRI
	bupropion ER/SR/XL			APLENZIN FORFIVO XL
	SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI)		Trazodone, buspirone, fluvoxamine, MAO inhibitors, TCA's, bupropion IR, and venlafaxine IR do not require prior authorization but will not count towards meeting preferred therapy requirements.	SSRI
	citalopram escitalopram fluoxetine capsules paroxetine IR/CR sertraline		Clients will not be allowed to be on more than one antidepressant, including fluvoxamine, bupropion IR, and venlafaxine IR, at one time with the exception of mirtazapine or bupropion with a SSRI or SNRI.	fluoxetine tablets (use preferred agent) VIIBRYD
	SEROTONIN/NORPINEPHRINE REUPTAKE INHIBITORS (SNRI)			SNRI
	venlafaxine ER capsules		**Duloxetine will be approved for clients with a diagnosis of osteoarthritis of the knee or chronic low back pain. ***Trintellix requires trial and failure of two preferred agents in any class Clients five (5) years of age and younger will require prior authorization before approval.	duloxetine** desvenlafaxine FETZIMA PRISTIQ venlafaxine ER tablets (use preferred agent)
			Dosage limits apply: bupropion ER/SR/XL: 450mg/day citalopram < 60 years of age: 60mg/day citalopram > 60 years of age: 30mg/day escitalopram: 30mg/day fluoxetine < 18 years of age: 90mg/day fluoxetine > 18 years of age: 120mg/day mirtazapine: 67.5mg/day paroxetine IR/CR < 18 years of age: 75mg/day paroxetine IR > 18 years of age: 90mg/day paroxetine CR > 18 years of age: 112.5mg/day sertraline: 300mg/day venlafaxine ER: 337.5mg/day	OTHER TRINTELLIX***

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT CHANGE HEALTHCARE FOR QUESTIONS</small>
ANTHYPERTENSIVES	ACE INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	benazepril captopril enalapril fosinopril lisinopril moexipril perindopril quinapril ramipril trandolapril			
	ACE INHIBITORS AND DIURETICS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ moexipril/HCTZ quinapril/HCTZ			
	ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)		Trial and failure of an ACE Inhibitor greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for preferred ARB. Non-preferred ARBs and ARB/diuretic combinations also require a history of ALL preferred ARBs before approval can be given.	
	irbesartan losartan valsartan			
ARBs AND DIURETICS		Trial and failure of an ACE Inhibitor greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for preferred ARB. Non-preferred ARBs and ARB/diuretic combinations also require a history of ALL preferred ARBs before approval can be given.		
	irbesartan HCTZ losartan HCT			
ALPHA-BLOCKERS			clonidine patch (BRAND IS PREFERRED) NEXICLON XR (use preferred agent)	
	CATAPRES PATCHES* clonidine			
ANTIVIRALS	PROTEASE INHIBITORS			NORVIR solution (use preferred agent)
	APTIVUS CRIVIVAN INVIRASE LEXIVA NORVIR TABLETS PREZISTA REYATAZ VIRACEPT			
ANTIPSYCHOTICS	ATYPICAL ANTIPSYCHOTICS		**Quetiapine doses less than 100mg will require prior authorization without a diagnosis of mood disorder or major depressive disorder. For titration doses, contact the Change Healthcare Pharmacy Help Desk for an override. Clients five (5) years of age and younger will require prior authorization before approval. *Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for REXULTI or VRAYLAR. Dosage limits apply: aripiprazole <13 years of age: 23mg/day aripiprazole ≥13 years of age: 45mg/day FANAPT: 36mg/day INVEGA: 18mg/day LATUDA: 240mg/day olanzapine <13 years of age: 15mg/day olanzapine ≥13 years of age: 30mg/day quetiapine <13 years of age: 600mg/day quetiapine 13-17 years of age: 900mg/day quetiapine >17 years of age: 1200mg/day risperidone ≤ 17 years of age: 5mg/day risperidone >17 years of age: 24mg/day SAPHRIS: 30mg/day ziprasidone ≤17 years of age: 180mg/day ziprasidone >17 years of age: 300mg/day	aripiprazole ODT (BRAND IS PREFERRED) paliperidone (BRAND IS PREFERRED) REXULTI* SEROQUEL XR (use preferred agent) VRAYLAR*
	ABILIFY MAINTENA ABILIFY ODT* aripiprazole tab/solution ARISTADA FANAPT INVEGA* INVEGA SUSTENNA/TRINZ LATUDA olanzapine quetiapine RISPERDAL CONSTA risperidone SAPHRIS ziprasidone ZYPREXA RELPREVV			
	SPECIAL ATYPICAL ANTIPSYCHOTICS		Dosage limits apply: 1350mg/day	VERSACLOZ Suspension (use preferred agent)
	clozapine/ODT			

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR HEALTH CARE PROVIDER</small>
CHOLESTEROL	BILE ACID SEQUESTERANT		Trial and failure of ALL preferred agents greater than or equal to six (6) months in the last 12 months will be required before approval can be given for a non-preferred agent.	WELCHOL
	cholestyramine/light colestipol			
	INTESTINAL CHOLESTEROL INHIBITOR			
	ZETIA			
	NIACIN			
	NIASPAN*			niacin ER (BRAND IS PREFERRED)
	STATINS, LOW POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization. Prior authorization will be required for clients under the age of 10.	fluvastatin/ER
lovastatin pravastatin				
STATINS, HIGH POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization. Prior authorization will be required for clients under the age of 10.	CRESTOR LIVALO	
atorvastatin simvastatin				
STATIN COMBINATIONS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Prior authorization will be required for clients under the age of 10.	amlodipine/atorvastatin (BRAND IS PREFERRED)	
CADUET* VYTORIN				
TRIGLYCERIDE LOWERING AGENTS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ANTARA fenofibric fenofibrate 43. 50. 120. 130. and 150mg LIPOFEN omega-3-acid VASCEPA	
fenofibrate 48, 54, 67, 134, 145, 160, and 200mg gemfibrozil				
CONTRACEPTIVES	ORAL CONTRACEPTIVES			
	altavera alyacen 1-35, 7/7/7 amethyst azurette apri aubra aviane balziva bekyree blisovi 1-20 FE/24, 1.5-30 FE briellyn camila caziant chateal cyclafem 1-35, 7/7/7 cyred cryselle dasetta 1-35, 7/7/7 deblitane delyla DESOGEN deso/ethinyl estradiol elinest emoquette enpresse enskyce errin estarylla falmina FEMCON FE CHEWABLE gianvi gildagia gildess 1-20/FE/24, 1.5-30/FE heather jencycla jolessea jolvette juleber junel 1-20/FE/24, 1.5-30/FE kariva kelnor kimidess kurvelo larin 1-20/FE/24, 1.5-30/FE leena lessina levonest levonor/ethi levora lomedica 24 FE LOSEASONIQUE* low-ogestrel lutera lyza		amethia/LO (BRAND IS PREFERRED) aranelle (use preferred agent) ashlyna (BRAND IS PREFERRED) BEYAZ (PA required) BREVICON (use preferred agent) camrese/LO (BRAND IS PREFERRED) daysee (BRAND IS PREFERRED) drospir/ethi (use preferred agent) estarylla tri-lo (BRAND IS PREFERRED) FALESSA KIT (use preferred agent) introvale (use preferred agent) layolis FE chewable (PA required) levonorgest/ethinyl estrad (91-Day) levonorgest/ethinyl estradiol (Continuous) (use preferred agent) levonorgest/ethinyl estradiol/LO (84-7) (BRAND IS PREFERRED) LO LOESTRIN (PA required) LO MINASTRIN FE (PA required) loryna (use preferred agent) MINASTRIN 24 FE CHEWABLE (PA required) NATAZIA (PA required) norgest/ethi estradiol lo (BRAND IS PREFERRED) NATAZIA (PA required) NECON 1/50-28 (use preferred agent) nikki (use preferred agent) noreth/ethin FE chewable (PA required) NORINYL 1/35 (use preferred agent) ouasense (use preferred agent) QUARTETTE (PA required) SAFYRAL (PA required) tri-lo sprintec (BRAND IS PREFERRED) trinessa lo (BRAND IS PREFERRED) wymzya FE chewable (BRAND IS PREFERRED) zenchent FE chewable (BRAND IS PREFERRED)	

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOURS HEALTH CARE FOR QUESTIONS</small>
CONTRACEPTIVES continued	marlissa microgestin 1-20/FE/24, 1.5-30/FE MODICON mono-linyah mononessa myzila NECON 0.5-35, 1-35, 7/7/7, 10/11-28 nora-be norgest/ethinyl estradiol norethindrone norlyroc noreth/ethin 1-20/FE/24 NORINYL 1/50-28 nortrel 0.5-35, 1-35, 7/7/7 ocella OGESTREL orsythia ORTHO TRI-CYCLEN LO* ORTHO-NOVUM 1/35, 7/7/7* phillith pimtrea pirmella 1-35, 7/7/7 portia previfem reclusen SEASONIQUE* settakin sprintec sharobel sronyx syeda tilia FE tri-estaryll tri-legest FE tri-linyah trinessa TRI-NORINYL* tri-previfem tri-sprintec trivora velivet vestura vienna viorele vyfemla wera 0.5-35 YAZ zarah zenchent ZOVIA			
CORTICOSTEROIDS	ORAL CORTICOSTEROIDS			CELESTONE (use preferred agent)
	budesonide cortisone acetate dexamethasone/intensol hydrocortisone methylprednisone prednisolone prednisone			

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS CELL IS NOT FULL INCLUSIVE PLEASE CONSULT PROVIDER MANUAL FOR QUESTIONS</small>
DIABETES	DIABETES AGENTS			
	BIGUANIDES			
	metformin/ER			metformin SR 24HR osmotic release(<i>use preferred agent</i>) metformin SR 24HR modified release (<i>use preferred agent</i>) RiOMET (<i>use preferred agent</i>)
	α-GLUCOSIDASE INHIBITORS			GLYSET*
	acarbose		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	MEGLITINIDES			
	STARLIX*		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	nateglinide (BRAND IS PREFERRED) repaglinide
	THIAZOLIDINEDIONES			
	pioglitazone		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACTOSPLUS MET (<i>use separate agents</i>) AVANDIA AVANDAMET (<i>use separate agents</i>)
	SULFONYLUREAS			
	glimepiride/ER glipizide/ER glyburide/ER		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS			
		JANUVIA ONGLYZA	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	alogliptin GLYXAMBI (<i>use separate preferred agents</i>) TRADJENTA
	DPP-4 INHIBITOR COMBO AGENTS			
		JANUMET/XR KOMBIGLYZE	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	alogliptin/metformin alogliptin/pioglitazone JENTADUETO JUVISYNC
	INCRETIN MIMETICS (GLP-1 RECEPTOR AGONISTS)			
	BYDUREON VICTOZA	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent. Dosage Limits Apply: Victoza: 1.8mg/day	BYETTA TANZEUM TRULICITY	
SGLT2 INHIBITORS				
	FARXIGA	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	GLYXAMBI (<i>use separate preferred agents</i>) INVOKANA JARDIANCE	
SGLT2 INHIBITOR COMBO AGENTS				
	XIGDUO XR	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	INVOKAMET SYNJARDY	
LONG-ACTING INSULIN				
LANTUS SOLOSTAR LANTUS vial LEVMIR		Prior authorization will be required when using two different delivery forms of the same type of insulin concurrently	LANTUS OPTICLIK (<i>use preferred agent</i>) TOUJEO (<i>use preferred agent</i>) TRESIBA (<i>use preferred agent</i>)	
DIABETIC METERS/TEST STRIPS				
	FREESTYLE INSULINX FREESTYLE LITE FREESTYLE FREEDOM LITE ONE TOUCH ULTRA ONE TOUCH ULTRA 2 ONE TOUCH ULTRA MINI ONE TOUCH ULTRASMART ONE TOUCH VERIO ONE TOUCH VERIO FLEX PRECISION XTRA	Quantity limits apply: Insulin Dependent Clients: 10 strips/day Non-Insulin Dependent Clients: 4 strips/day Clients are limited to 1 meter/365 days	ALL OTHER METERS AND TEST STRIPS	
EAR	ANTIBIOTIC/STEROID COMBINATION			
	CIPRODEX Neo/Poly/Hc Suspension and Solution			ciprofloxacin 0.2% (<i>use preferred agent</i>) CIPRO HC (<i>use preferred agent</i>) COLY-MYCIN S (<i>use preferred agent</i>) CORTISPORIN-TC (<i>use preferred agent</i>) FLUOCINOLONE ACET OIL 0.01% (<i>use preferred agent</i>) ofloxacin (<i>use preferred agent</i>)
FIBROMYALGIA	FIBROMYALGIA STEP 1			
	amitriptyline cyclobenzaprine			
	FIBROMYALGIA STEP 2			
	SAVELLA	Trial and failure of a Step 1 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 2 agent.		
FIBROMYALGIA STEP 3				
	duloxetine LYRICA	Trial and failure of a Step 1 agent and a Step 2 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 3 agent. Dosage Limits Apply: Lyrica: 600mg/day		
GASTROINTESTINAL	BOWEL PREP			
	PREPOPIK			
	DIGESTIVE ENZYMES			
CREON 3000, 6000, 12000, 24000, and 36000 units pancrelipase ZENPEP		Prior authorization required.	PANCREAZE PERTZYE TRI-PASE ULTRESA VIOKASE	
IRRITABLE BOWEL SYNDROME AGENTS				
	AMITIZA LINZESS	Client must have a diagnosis of chronic idiopathic constipation or Irritable Bowel Syndrome (IBS) with constipation.		

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR HEALTH CARE FOR QUESTIONS</small>
GASTROINTESTINAL continued	OPIOID-INDUCED CONSTIPATION AGENTS		Client must have a diagnosis of opioid-induced constipation and a three (3) month trial and failure of a secretory agent to receive the preferred agent. To receive the non-preferred agent, client must have a diagnosis of opioid-induced constipation, a three (3) month trial and failure of a secretory agent, and a three (3) month trial and failure of the preferred agent. Movantik will be approved with a diagnosis of cancer or for clients in hospice or palliative care. *Movantik will be approved for a diagnosis of cancer or for clients in hospice or palliative care.	MOVANTIK*
		AMITIZA		
		PROTON PUMP INHIBITORS	Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Lansoprazole solutabs will be approved for children less than or equal to 8 years of age.	ACIPHEX SPRINKLES amox/clairth/lanso pack (use separate agents) DEXILANT esomeprazole 24.65mg and 49.3mg lansoprazole solutabs NEXIUM* omeprazole 20.6mg capsules (use preferred agent) omeprazole tablets (use preferred agent) omeprazole/sodium bicarbonate OMECLAMOX (use separate agents) rabeprazole VIMOVO (use separate agents)
	lansoprazole capsules omeprazole capsules pantoprazole			
	MESALAMINE	Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	APRISO ASACOL/HD CANASA LIALDA PENTASA 500MG (use preferred) ROWASA	
DELZICOL mesalamine enema PENTASA 250MG ONLY				
GROWTH HORMONE	GROWTH HORMONE		PA is required for use outside of FDA-approved indications. Evaluation by an endocrinologist is preferred. Clinical evidence of improved growth will be required on a yearly basis to support ongoing utilization. Clinical evidence of need for growth hormone will be required for adult growth hormone deficiency and pediatric growth failure due to inadequate endogenous growth hormone. Trial and failure of two (2) preferred agents within the last 12 months will be required for the following indications: Pediatric: Growth failure due to inadequate endogenous growth hormone, Prader-Willi syndrome, children born small for gestation, Turner syndrome. Adult: Replacement for those with growth hormone deficiency.	HUMATROPE OMNITROPE SAIZEN SEROSTIM TEV-TROPIN ZORBIVIE
		GENOTROPIN NORDITROPIN NUTROPIN AQ		
HEART FAILURE	NEPRILYSIN INHIBITOR AND ARB COMBO			
	ENTRESTO			
HEPATITIS C	NS5A INHIBITOR		Limited to FDA approved indication. Prior authorization will be required prior to use of Daklinza. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org .	
		DAKLINZA		
		NUCLEOTIDE ANALOG POLYMERASE INHIBITOR	Limited to FDA approved indication. Prior authorization will be required prior to use of Sovaldi. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org .	
		SOVALDI		
		PROTEASE INHIBITOR	Limited to FDA approved indication. Prior authorization will be required prior to use of Olysio. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org .	
	OLYSIO			
	HEP C COMBO AGENTS		Limited to FDA approved indication. Prior authorization will be required prior to use of Harvoni, Technivie, Viekira Pak, or Zepatier. *Testing for the presence of virus with NS5A resistance-associated polymorphisms will be required prior to Zepatier being approved. Ribavirin will be required for any client that is positive for the above mentioned polymorphism. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org .	
	EPCLUSA HARVONI TECHNIVIE VIEKIRA PAK/XR ZEPATIER*			

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.					
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR HEALTH CARE PROVIDER</small>	
IMMUNOMODULATORS	ANKYLOSING SPONDYLITIS (AS)		Client must have diagnosis of AS prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of AS and a 56-day trial and failure of both preferred agents. Quantity Limits apply for all diagnoses: Enbrel 25mg - limited to 10 per month Enbrel 50mg - limited to 5 per month Humira 20mg - limited to 10 per month Humira 40mg - limited to 5 per month	CIMZIA COSENTYX REMICADE SIMPONI	
		ENBREL HUMIRA			
		CROHN'S		Client must have diagnosis of Crohn's prior to approval of the preferred agent. To receive a non-preferred agent, client must have a diagnosis of Crohn's and a 56-day trial and failure of the preferred agent.	CIMZIA REMICADE TYSABRI (additional criteria applies)
		HUMIRA			
		HIDRODENTITIS SUPPURATIVA		Humira will not be covered as a first line agent for the diagnosis for hidrodentitis suppurativa.	
		JUVENILE IDIOPATHIC ARTHRITIS (JIA)		Client must have diagnosis of JIA prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of JIA and a 56-day trial and failure of both preferred agents.	ACTEMRA ORENCIA
			ENBREL HUMIRA		
		PSORIATIC ARTHRITIS (PA)		Client must have diagnosis of PA prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of PA and a 56-day trial and failure of both preferred agents.	CIMZIA COSENTYX OTEZLA REMICADE SIMPONI
			ENBREL HUMIRA		
		PLAQUE PSORIASIS (PP)		Client must have diagnosis of PP prior to approval of a step 1 agent (Enbrel or Humira). To receive the step 2 agent (Cosentyx), client must have a diagnosis of PP and a 56-day trial and failure of Humira. To receive a non-preferred agent, client must have a diagnosis of PP and a 56-day trial and failure of both preferred agents.	OTEZLA REMICADE STELARA TALTZ
		STEP 1 AGENTS			
			ENBREL HUMIRA		
		STEP 2 AGENT			
			COSENTYX		
	RHEUMATOID ARTHRITIS (RA)		Client must have diagnosis of RA and a 56-day trial and failure of methotrexate prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of RA and a 56-day trial and failure of both preferred agents.	ACTEMRA CIMZIA KINERET ORENCIA REMICADE RITUXAN SIMPONI XELJANZ/XR	
		ENBREL HUMIRA			
	ULCERATIVE COLITIS (UC)		Client must have diagnosis of UC prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of UC and a 56-day trial and failure of the preferred agent.	REMICADE	
		HUMIRA			
	UVEITIS		Client must have diagnosis of non-infectious intermediate, posterior, and panuveitis in adult patients		
		HUMIRA			
INSOMNIA	NON-BENZODIAZEPINES		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Prior authorization will be required for clients under the age of 18. Rozerem is non-preferred without a history of substance abuse Prior authorization will be required when a client is taking more than one insomnia agent concurrently. Dosage limits apply: zaleplon: 30mg/day zolpidem: 15mg/day	BELSOMRA EDLUAR (additional criteria applies) eszopiclone INTERMEZZO (additional criteria applies) ROZEREM zolpidem ER ZOLPIMIST (additional criteria applies)	
		zaleplon zolpidem			
MIGRAINE	TRIPTANS		Trial and failure of all preferred agents will be required for approval of a non-preferred agent. Rizatriptan will be approved for clients between 6 and 17 years of age. Quantity limits apply: naratriptan 1mg: 25 tabs/34 days naratriptan 2.5mg: 10 tabs/34 days sumatriptan vials: 2 vials/34 days sumatriptan nasal: 6 bottles/34 days sumatriptan 25mg: 41 tabs/34 days sumatriptan 50mg: 20 tabs/34 days sumatriptan 100mg: 10 tabs/34 days	almotriptan frovatriptan ONZETRA (use preferred agent) RELPAX rizatriptan TREXIMET ZEMBRACE (use preferred agent) ZECUITY PAD (use preferred agent) zolmitriptan	
		naratriptan sumatriptan			
MULTIPLE SCLEROSIS	STEP 1 MS AGENTS		Trial and failure of one injectable preferred agent will be required before approval can be given for the step 2 MS agent (Gilenya).	COPAXONE 40MG/ML (use preferred agent) EXTAVIA LEMTRADA PLEGRIDY TECFIDERA TYSABRI (additional criteria applies) ZINBRYTA	
	IMMUNOMODULATOR (GLATIRAMER INJECTION)				
		COPAXONE 20MG/ML			
	INTERFERON		Trial and failure of a two preferred agents (each from a separate class) will be required before approval can be given for a non-preferred agent. For Tysabri, in addition to the above criteria, additional prior authorization criteria applies.		
		AVONEX BETASERON REBIF			
	PYRIMIDINE SYNTHESIS INHIBITOR				
	AUBAGIO				
STEP 2 MS AGENTS					
	GILENYA				
NEUROPATHIC PAIN	TRICYCLIC ANTIDEPRESSANTS		For the diagnosis of neuropathic pain, trial and failure of a tricyclic antidepressant greater than or equal to a 12 week supply AND trial and failure of gabapentin at a dose of 3600mg per day for greater than or equal to a 12 week supply in the last 12 months will be required before approval can be given for a non-preferred agent.	duloxetine LYRICA	
		amitriptyline desipramine imipramine nortriptyline			
	GABAPENTIN				
		gabapentin			

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR HEALTH CARE PROVIDER</small>
NSAIDS	NSAIDs		Trial and failure of two (2) preferred agents each greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Dosing and quantity limits apply for ketorolac (limit 5days/34 days; max dose 40mg/day for oral tablets).	CALDOLOR (use preferred agent) CAMBIA POWDER (use preferred agent) celecoxib diclofenac 1.5% solution (additional criteria applies) diclofenac 3% gel (additional criteria applies) fenoprofen FLECTOR (additional criteria applies) mefenamic acid NEOPROFEN (use preferred agent) SPRIX (additional criteria applies) TIVORBEX (use preferred agent) VIVLODEX (use preferred agent) VOLTAREN (additional criteria applies) ZIPSOR (use preferred agent) ZORVOLEX (use preferred agent)
OPHTHALMICS	OP. -ANTI-ALLERGICS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Emadine, Alomide, and Alocril will be approved for pregnancy. Alomide will be approved for children under the age of 3.	ALAMAST ALOCRIL ALOMIDE ALREX azelastine BEPREVE EMADINE epinastine ketotifen LASTACAPT olopatadine (BRAND IS PREFERRED) PAZEO
	OP. -ANTIBIOTICS- QUINOLONES		Trial and failure of a preferred agent greater than or equal to 5 days in the last 12 months will be required before approval can be given for a non-preferred agent. Azasite will be approved for pregnancy.	AZASITE BESIVANCE gatifloxacin IQUIX levofloxacin ZYMAR
	OP. -ANTI-INFLAMMATORY- NSAIDS		Trial and failure of ALL preferred agents each greater than or equal to 5 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACULAR/LS/PF (use preferred) ACUVAIL bromfenac 0.9% PROLENSA
	OP. -BETA-BLOCKERS		Trial and failure of three (3) preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Betoptic S will be approved for those with heart and lung conditions.	BETIMOL BETOPTIC S ISTALOL
	OP. -CARBONIC ANHYDRASE INHIBITOR		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	AZOPT
	OP. -COMBO PRODUCTS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	
	OP. -LFA-1 ANTAGONIST			
	OP. -PROSTAGLANDINS		Trial and failure of ALL preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	bimatoprost LUMIGAN 0.1% ZIOPTAN
	OP. -SYMPATHOMIMETICS		Trial of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	ALPHAGAN P 0.1% brimonidine 0.15% (BRAND IS PREFERRED)
	OSTEOPOROSIS	BISPHOSPHONATES		Trial and failure of a preferred agent greater than or equal to 12 months will be required before approval can be given for a non-preferred agent. Fosamax liquid will be approved for clients that have difficulty swallowing.
NASAL CALCITONIN				
OVERACTIVE BLADDER	OVERACTIVE BLADDER AGENTS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Oxytrol will be approved for clients that have an inability to swallow.	ENABLEX* GELNIQUE GEL 10% MYRBETRIQ OXYTROL DIS tolterodine/ER trospium/ER
PHOSPHATE BINDERS	PHOSPHATE BINDERS		Prior authorization required for non-preferred agents.	AURYXIA FOSRENOL RENAGEL 800mg (use preferred agent) sevelamer VELPHORO

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES
PLATELET AGGREGATE INHIBITORS	THIENOPYRIDINE DERIVATIVES		Prior authorization required for clients on antiplatelet therapy greater than one (1) year.	
	clopidogrel EFFIENT ticlopidine			
	CPTP DERIVATIVES		Prior authorization is required.	BRILINTA
	PAR-1 ANTAGONIST		Client must have diagnosis reduction of thrombotic cardiovascular events with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). Must be used in conjunction with aspirin or clopidogrel.	
		ZONTIVITY		
PROGESTIN	PROGESTIN MAKENA		Prior authorization is required.	
PROSTATE	5-ALPHA-REDUCTASE INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	dutasteride dutasteride/tamsulosin (<i>use separate agents</i>)
	finasteride			
	ALPHA BLOCKERS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	alfuzosin dutasteride/tamsulosin (<i>use separate agents</i>) RAPAFLO
	doxazosin tamsulosin terazosin			
PULMONARY ANTIHYPERTENSIVES	5-ALPHA-REDUCTASE INHIBITORS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
		ADCIRCA REVATIO SUSPENSION sildenafil (Revatio A/B rated generic)		
	ENDOTHELIN RECEPTOR ANTAGONISTS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	OPSUMIT (<i>use preferred agent</i>)
		LETAIRIS TRACLEER		
	PROSTACYCLINE VASODILATORS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
		ORENITRAM		
		PROSTACYCLINE RECEPTOR AGONIST	Prior authorization required.	UPTRAVI (<i>use preferred pulmonary HTN agent</i>)
RESTLESS LEG SYNDROME	RESTLESS LEG SYNDROME gabapentin pramipexole ropinirole		Client must have a diagnosis of Restless Leg Syndrome (RLS). Trial and failure of gabapentin greater than or equal to 60 days and a trial and failure of a dopamine agonist greater than or equal to 60 days in the last 12 months will be required before approval can be given for a non-preferred agent. *Neupro will be approved for clients with difficulty swallowing or for clients with a diagnosis of Parkinson's Disease.	HORIZANT NEUPRO*
SKELETAL MUSCLE RELAXANTS	MUSCLE RELAXANTS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months, along with a medical diagnosis of muscle spasticity will be required before approval can be given for a non-preferred agent. Cyclobenzaprine will require a prior authorization for clients concurrently taking a tricyclic antidepressant.	carisoprodol chlorzoxazone cyclobenzaprine ER metaxalone methocarbamol orphenadrine tizanidine capsules (<i>use preferred agent</i>) Carisoprodol is limited to 84 tabs/365 days
	baclofen cyclobenzaprine tizanidine tablets			
STIMULANT	AMPHETAMINES LONG ACTING AMPHETAMINES		Clients over the age of 17 must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, MS fatigue (see MS Fatigue criteria below), or refractory depression (see refractory depression criteria below).	AMPHETAMINES ADZENYS XR amphetamine salts combo XR (BRAND IS PREFERRED) dextroamphetamine CR capsules (BRAND IS PREFERRED) DYNAVEL ZENZEDI 2.5 AND 7.5MG TABLETS
	IMMEDIATE RELEASE AMPHETAMINES		Diagnosis of MS fatigue will require a fatigue severity scale score of 5.0, a 60-day trial of amantadine and discontinuation of medications that may contribute to drowsiness and fatigue.	
		amphetamine salts combo* dextroamphetamine tablets		
	METHYLPHENIDATES LONG ACTING METHYLPHENIDATES		Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant.	METHYLPHENIDATES APTENSIO XR dexmethylphenidate ER (BRAND IS PREFERRED) methylphenidate ER/CR/SR capsules (METADATE CD/RITALIN LA) QUILLICHEW QUILLIVANT XR SUSPENSION
		DAYTRANA FOCALIN XR* methylphenidate ER/CR/SA/SR tablets***		
	IMMEDIATE RELEASE METHYLPHENIDATES		Prior Authorization will be required for clients under the age of 4.	
		dexmethylphenidate methylphenidate tablets methylphenidate tablets		
			Vyvanse will be approved for the diagnosis of binge-eating disorder for clients 18 years of age and older. Authorizations will be approved for 12 weeks, and further use of Vyvanse for this diagnosis will require additional documentation prior to approval. *Only authorized generics for Concerta will be covered.	
			Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use.	
			Trial and failure of two (2) preferred agents (each from a different class: methylphenidate and amphetamine) greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Dosage limits apply: amphetamine salts combo XR: 60mg/day amphetamine salts combo: 60mg/day amphetamine salts combo (narcolepsy): 90mg/day DAYTRANA: 45mg/9 hour patch/day dextroamphetamine: 90mg/day dextroamphetamine CR: 90mg/day dexmethylphenidate: 30mg/day FOCALIN XR < 13 years of age: 45mg/day FOCALIN XR > 13 years of age: 60mg/day methylphenidate/ER: 90mg/day VYVANSE: 105mg/day	

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR HEALTH CARE FOR QUESTIONS</small>
STIMULANT-LIKE AGENTS	SELECTIVE ALPHA-ADRENERGIC AGONIST		To obtain the non-preferred agent , client must meet the following criteria: Client must have a diagnosis of ADD or ADHD Prior authorization will be required for clients under the age of 4. To receive Kapvay, clients must have completed a 14 day trial of clonidine IR with <u>benefit</u> in the previous 12 months.	KAPVAY*
	clonidine			
	GUANFACINE AGENTS		To obtain the non-preferred agent , client must meet the following criteria: Client must have a diagnosis of ADD or ADHD Prior authorization will be required for clients under the age of 4. To receive Intuniv, clients must have: A) a trial and failure of a stimulant greater than or equal to a 14 day supply, or B) a trial and failure of Strattera greater than or equal to a 30 day supply, or C) a contraindication to ADHD medications (including stimulant and non-stimulant), or D) a diagnosis of a TIC disorder, AND E) a 14 day trial of guanfacine <u>with benefit</u> in the previous 12 months.	guanfacine ER
	guanfacine			
SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR		Clients must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, or refractory depression (see refractory depression criteria below). Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant. Prior Authorization will be required for clients under the age of 4. Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use. Dosage limits apply: STRATTERA: 150mg/day		
	STRATTERA			
TOPICAL AGENTS	IMPETIGO ANTIBIOTICS		Trial and failure of ALL preferred agents greater than or equal to 7 days in the past 90 days. Use smallest size appropriate for 7 day trial.	ALTABAX
	gentamicin mupirocin			
	BENZOYL PEROXIDE/CLINDAMYCIN COMBOS		Clients must be 12 to 20 years of age and have a diagnosis of acne vulgaris. Requires prior authorization for clients less than 12 years of age. Acne combinations are limited to clients under the age of 21.	ACANYA benzoyl peroxide/clindamycin (BRAND IS PREFERRED)
		BENZAFLIN* clindamycin/benzoyl peroxide 1.2 (1)-5% (Refrig)		
	CORTICOSTEROIS LOW POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	PANDEL prednicarbate 0.1% (C,O) TEXACORT 2.5% (S)
	alclometasone desonide DESOWEN 0.05% (L) fluocinolone 0.01% hydrocortisone butyrate 0.1% (C) hydrocortisone 1%, 2.5% (C,L,O) SYNALAR 0.01%			
	MEDIUM POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	Clocortolone Pivalate CORDRAN/SP fluticasone 0.05% (L) hydrocortisone butyrate 0.1% (O) TOPICORT LP TRIANEX
	betamethasone valerate CUTIVATE 0.05% (C) DERMATOP 0.1% (C) desoximetasone 0.05% (C) ELOCON 0.1% fluocinolone 0.025% fluticasone 0.05% (C) hydrocortisone probutate 0.1% (C) mometasone SYNALAR 0.025% TOPICORT 0.05% (C) triamcinolone 0.025%, 0.1%			
HIGH POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	APEXICON amcinonide 0.1% (C,L,O) augmented betamethasone 0.05% (G,L,O) clobetasol 0.05% (L) desoximetasone 0.05%, 0.25% (C,G,O) fluocinonide 0.1% (C) HALOG	
betamethasone dipropionate clobetasol/E 0.05% (C,G,O,S) diflorasone DIPROLENE 0.05% (L) fluocinonide flurandrenolide fluticasone 0.005% (O) halobetasol TEMOVATE/E TOPICORT 0.25% (C) triamcinolone 0.5% ULTRAVATE 0.05%				

WYOMING MEDICAID
Preferred Drug List (PDL) - August 31, 2016

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.					
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR MEDICAID CASE QUESTIONS</small>	
TOPICAL AGENTS continued	IMMUNOMODULATORS		Trial and failure of a preferred medium potency topical corticosteroid greater than or equal to a 21 day trial <u>and</u> a trial and failure of a preferred high potency topical corticosteroid greater than or equal to a 21 day trial in the last 90 days. For clients less than two (2) years of age, a trial and failure of a preferred low potency corticosteroid greater than or equal to a 21 day trial <u>and</u> a trial and failure of a preferred medium potency topical corticosteroid greater than or equal to a 21 day trial in the last 90 days.		
		ELIDEL tacrolimus ointment			
	SALICYLIC ACID				
	salicylic acid cream 6% salicylic acid lotion 6% salicylic acid shampoo 6%				All other topical salicylic acid formulations.
	SCABICIDES/PEDICULICIDES		Trial and failure of a preferred agent in the last 12 months.		
NATROBA permethrin solution SKLICE			LINDANE OVIDE permethrin cream ULESFIA		
UREA					
ALUVEA CREAM 33% UMECTA EMULSION umecta mousse aerosol 40% urea lotion 40% urea lotion 45%			All other topical urea formulations.		